Thursday, November 18, 2021

Cardiff Oncology Finds $15M From Pfizer

San Diego-based precision medicine company Cardiff Oncology said this morning that the publicly traded company has received a $15M equity investment from Pfizer. According to the company, the investment comes as part of the Pfizer Breakthrough Growth Initiative, a program focused on "funding innovative science to meet patient needs". According to the company, Pfizer VP Adam Schayowitz joins the company's Scientific Advisory Board. Cardiff Oncology's lead investigational drug, onvansertib, is a Polo-like Kinase 1 (PLK1) inhibitor, and is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics.